MOTS-c is not FDA-approved and long-term human safety data does not exist
A recent clinical trial including patients with Parkinson's disease reported that systemically administered exenatide, a GLP1 receptor agonist, in a licensed dose for the treatment of Type 2 diabetes, did cross the bloodbrain barrier (Athauda et al., 2017)
The primary measured outcome for the study was a composite of all-cause mortality, heart attack, and ischemic stroke
First, gastrointestinal side effects such as nausea, vomiting, and abdominal distension can increase the incidence of postoperative nausea and vomiting (PONV)
When you buy the pre-blended vial, both peptides are already measured and combined you reconstitute once and you're ready